EU approves Saxenda (liraglutide 3 mg) for Obesity-Novo Nordisk
Novo Nordisk has announced that the European Commission has granted marketing authorisation for Saxenda (liraglutide 3 mg) for the treatment of obesity. The authorisation covers all 28 European Union (EU) member states. The drug was approved by the FDA in December 2014.
Comment: Saxenda is up against stiff competition in the obesity market, at least in the USA, with Belviq (lorcaserin HCl) and Qsymia (phentermine/topiramate) both approved for obesity. Saxenda may be at a disadvantage, since it is an injectable medicine, but working in the drug's favour is Novo Nordisk's years of experience marketing diabetes therapies. In Europe, Alli (orlistat) is the only approved therapy for obesity apart from Saxenda.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins